Beta Bionics, Inc. (BBNX)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$19.16-0.93%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Beta Bionics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	32.28M
EPS	—	-0.479
FY 2026 · Annual
Revenue	$131M–$136M	126.63M
EPS	—	-2.016
Gross margin	58.5%–59.5%	—
FY 2027 · Annual
Revenue	—	182.64M
EPS	—	-2.082

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Gross margin improves to at least 57.5% in 2026	Gross margin is expected to improve to about 58.5%.	Intact	Gross margin falls below 57.5% in 2026	Gross margin: 59.04% FY2026-Q2; GAAP. Published target: >= 57.5% gross margin in 2026. Target period is not explicitly aligned with this observation. Source published Jul 29, 202659.044763 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8989b8bc-2c4a-4683-b2aa-776f058a7ca9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Gross margin improved from 52.5% in 2025-Q4 to 59.3% in 2026-Q2, exceeding prior guidance. Management raised 2026 gross margin guidance to 58.5%-59.5%. The trajectory is delivering improved margin consistent with management's stated goals. Delivery assessment Oct 24, 2026
Full commercialization of Mint by end of Q2 2027	A primary condition in Beta Bionics, Inc.'s published investment case. The stated target is Mint fully commercialized by 2027-Q2.	Improving	Mint commercialization delayed beyond 2027-Q2	FDA clearance obtained 2026-09-14; launch expected Q1 2027 vs target Q2 2027 FDA cleared Mint on Sept 14, 2026; company expects full US commercial launch in Q1 2027. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
2026 revenue reaches at least $131 million	A primary condition in Beta Bionics, Inc.'s published investment case. The stated target is >= $131 million revenue in 2026.	Intact	2026 revenue falls below $131 million	Revenue: $32.013M FY2026-Q2; GAAP. Published target: >= $131 million revenue in 2026. Target period is not explicitly aligned with this observation. Source published Jul 29, 202632,013,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8989b8bc-2c4a-4683-b2aa-776f058a7ca9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.08

Unavailable → $-2.08 · observed estimates

FY2027 revenue$0.18B

$0.18B → $0.18B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$179,547,530	3 / 10
2026-07-25	Unavailable	$179,547,530	3 / 10
2026-07-26	Unavailable	$179,547,530	3 / 10
2026-07-27	$-2.16	$179,551,526	6 / 8
2026-07-28	Unavailable	$179,547,530	2 / 10
2026-07-29	Unavailable	$179,291,020	2 / 11
2026-07-30	Unavailable	$179,942,200	2 / 11
2026-07-31	Unavailable	$179,764,670	2 / 11
2026-08-01	$-2.16	$179,508,210	5 / 8
2026-08-02	$-2.15	$179,762,755	5 / 8
2026-08-03	Unavailable	$179,764,670	2 / 11
2026-08-04	Unavailable	$179,764,670	2 / 11
2026-08-05	Unavailable	$179,764,670	2 / 11
2026-08-06	Unavailable	$179,764,670	2 / 11
2026-08-07	$-2.15	$179,762,755	5 / 8
2026-08-08	Unavailable	$179,764,670	2 / 11
2026-08-09	Unavailable	$179,764,670	2 / 11
2026-08-10	Unavailable	$179,764,670	2 / 11
2026-08-11	Unavailable	$179,764,670	2 / 11
2026-08-12	Unavailable	$179,764,670	2 / 11
2026-08-13	Unavailable	$179,764,670	2 / 11
2026-08-14	$-2.15	$179,762,755	5 / 8
2026-08-15	$-2.15	$179,762,755	5 / 8
2026-08-16	$-2.15	$179,762,755	5 / 8
2026-08-17	$-2.15	$179,762,755	5 / 8
2026-08-18	$-2.15	$179,762,755	5 / 8
2026-08-19	$-2.15	$179,762,755	5 / 8
2026-08-20	$-2.15	$179,762,755	5 / 8
2026-08-21	$-2.15	$179,762,755	5 / 8
2026-08-22	$-2.15	$179,651,709	6 / 8
2026-08-23	$-2.15	$179,651,709	6 / 8
2026-08-24	$-2.15	$179,651,709	6 / 8
2026-08-25	$-2.15	$179,651,709	6 / 8
2026-08-26	$-2.15	$179,651,709	6 / 8
2026-08-27	$-2.15	$179,651,709	6 / 8
2026-08-28	$-2.15	$179,651,709	6 / 8
2026-08-29	$-2.15	$179,651,709	6 / 9
2026-08-30	$-2.15	$179,651,709	6 / 9
2026-08-31	$-2.15	$179,651,709	6 / 9
2026-09-01	$-2.15	$179,651,709	6 / 9
2026-09-02	$-2.15	$179,651,709	6 / 9
2026-09-03	$-2.15	$179,651,709	6 / 9
2026-09-04	$-2.15	$179,651,709	6 / 9
2026-09-05	$-2.15	$179,651,709	6 / 9
2026-09-06	$-2.15	$179,651,709	6 / 9
2026-09-07	$-2.15	$179,651,709	6 / 9
2026-09-08	$-2.15	$179,651,709	6 / 9
2026-09-09	$-2.15	$179,651,709	6 / 9
2026-09-10	$-2.15	$179,651,709	6 / 9
2026-09-11	$-2.15	$179,651,709	6 / 9
2026-09-12	$-2.15	$179,651,709	6 / 9
2026-09-13	$-2.15	$179,621,459	6 / 9
2026-09-14	$-2.15	$179,621,459	6 / 9
2026-09-15	$-2.15	$179,621,459	6 / 9
2026-09-16	$-2.29	$181,490,528	6 / 9
2026-09-17	$-2.29	$181,490,528	6 / 9
2026-09-18	$-2.29	$181,490,528	6 / 9
2026-09-19	$-2.29	$181,490,528	6 / 9
2026-09-20	$-2.22	$181,492,778	6 / 9
2026-09-21	$-2.22	$181,492,778	6 / 9
2026-09-22	$-2.22	$181,492,778	6 / 9
2026-09-23	$-2.22	$181,492,778	6 / 9
2026-09-24	$-2.22	$181,492,778	6 / 9
2026-09-25	$-2.18	$182,154,872	6 / 9
2026-09-26	$-2.18	$182,154,872	6 / 9
2026-09-27	$-2.18	$182,154,872	6 / 9
2026-09-28	$-2.18	$182,154,872	6 / 9
2026-09-29	$-2.18	$182,154,872	6 / 9
2026-09-30	$-2.18	$182,154,872	6 / 9
2026-10-01	$-2.14	$182,154,872	6 / 9
2026-10-02	$-2.14	$182,154,872	6 / 9
2026-10-03	$-2.14	$182,154,872	6 / 9
2026-10-04	$-2.14	$182,154,872	6 / 9
2026-10-05	$-2.14	$182,154,872	6 / 9
2026-10-06	$-2.14	$182,154,872	6 / 9
2026-10-07	$-2.14	$182,154,872	6 / 9
2026-10-08	$-2.10	$182,154,872	7 / 9
2026-10-09	$-2.10	$182,154,872	7 / 9
2026-10-10	$-2.10	$182,154,872	7 / 9
2026-10-11	$-2.10	$182,152,795	7 / 9
2026-10-12	$-2.10	$182,152,795	7 / 9
2026-10-13	$-2.08	$182,641,881	7 / 9
2026-10-14	$-2.08	$182,641,881	7 / 10
2026-10-15	$-2.08	$182,641,881	7 / 10
2026-10-16	$-2.08	$182,641,881	7 / 10
2026-10-17	$-2.08	$182,641,881	7 / 10
2026-10-18	$-2.08	$182,641,881	7 / 10
2026-10-19	$-2.08	$182,641,881	7 / 10
2026-10-20	$-2.08	$182,641,881	7 / 10
2026-10-21	$-2.08	$182,641,881	7 / 10
2026-10-22	$-2.08	$182,641,881	7 / 10
2026-10-23	$-2.08	$182,641,881	7 / 10
2026-10-24	$-2.08	$182,641,881	7 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	3
2026-06-01	8	3
2026-07-01	8	3
2026-08-01	8	4
2026-09-01	9	4
2026-10-01	11	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

JefferiesOct 12

$30.00New observation · no comparable prior

BarclaysOct 6

$30.00New observation · no comparable prior

$0$16.50$33.00

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Gross margin improves to at least 57.5% in 2026Gross margin: 59.04%
2026 revenue reaches at least $131 millionRevenue: $32.013M

Next proof point

Oct 27, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-72.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Beta Bionics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a loss-making growth business with meaningful execution risk, rather than an established durable compounder. Its long-term thesis is on watch: revenue and gross margin goals are on track, but recent financial performance remains weak relative to its industry cohort.

What's priced into Beta Bionics, Inc.

The valuation model describes BBNX as carrying a durable premium of 2.35 times versus peers, while also showing an expectations gap of -0.53. In plain terms, the premium appears difficult to support if expectations are not met, though confidence in this valuation assessment is low and no fragility gates have fired.

What the fundamentals likely do

Near-term results have improved on the measures cited: quarterly revenue rose to $32.0 million by 2026-Q2, and gross margin reached 59.3%, above prior guidance. Management has raised 2026 revenue and margin guidance, while Mint received FDA clearance and is expected to launch in the US by 2027-Q2; however, the company remains loss-making, and the signal recently shifted from mildly favorable to mixed.

What Beta Bionics, Inc. hinges on

Over the next 1-3 years, the thesis depends on delivering the Mint launch and sustaining revenue and margin progress. A guidance cut after the recent increase would damage management credibility, while weaker job growth could weigh on cyclical healthcare names; continued strong results and guidance from sector peers would support the sector backdrop.